David Elkayam, MD
Allergy & Immunology · Bellingham, WANPI 1871589234
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,734 of the $39,433 with a category attached, or 60.2%. 28 manufacturers reported payments, led by Consortium Of Independent Immunology Clinics, LLC at 47.2% of the total. Among allergy & immunology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $229.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Consortium Of Independent Immunology Clinics, LLC$19K
- Optinose US, Inc.$11K
- Grifols USA, LLC$2K
- Pfizer$2K
- Alk-abello, Inc$2K
- Sanofi$446
- plus $3K from 22 others
Across 559 payments — averaging $3701.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$723K
- GSK$402K
- Merck$240K
- Optinose US, Inc.$194K
- Incyte Corporation$106K
- Bayer$97K
- plus $308K from 9 others
Across 2 payments — averaging $1000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Consortium Of Independent Immunology Clinics, LLC$2K
What the payments were for
- Consulting fees$23,73460%
- Speaking & faculty fees$8,06520%
- Travel & lodging$2,0265%
- Food & beverage$5,54914%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Consortium Of Independent Immunology Clinics, LLC | 3 | $18,600 |
| Optinose US, Inc. | 22 | $11,151 |
| Grifols USA, LLC | 6 | $2,488 |
| Pfizer | 4 | $1,726 |
| Alk-abello, Inc | 6 | $1,671 |
| Sanofi | 16 | $446 |
| AstraZeneca | 14 | $372 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $330 |
| Genentech USA, Inc. | 7 | $312 |
| Amgen | 9 | $263 |
| Novartis | 9 | $231 |
| Octapharma USA, Inc. | 2 | $195 |
| CSL Behring | 10 | $193 |
| Pharming Healthcare, Inc. | 8 | $188 |
| Blueprint Medicines Corporation | 4 | $175 |
| GSK | 13 | $172 |
| Regeneron Healthcare Solutions, Inc. | 6 | $166 |
| Biocryst US Sales Co., LLC | 5 | $147 |
| Merck | 4 | $140 |
| Circassia Inc. | 2 | $115 |
| AbbVie | 1 | $90 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| ADMA Biomanufacturing LLC | 3 | $54 |
| Kaleo, Inc. | 2 | $38 |
| Tersera Therapeutics LLC | 1 | $36 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,433 in reported general payments places this provider in the 90th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 18 | $63,226 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,404 |
| DuleraMometasone/Formoterol | 14 | $7,959 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,140 |
| Epinephrine | 17 | $5,886 |
| Qvar RedihalerBeclomethasone Dipropionate | 19 | $5,806 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,318 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,312 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $1,194 |
| Azelastine Hcl | 28 | $1,048 |
| Ipratropium Bromide | 20 | $819 |
| Montelukast Sodium | 69 | $627 |
| Fluticasone Propionate | 18 | $311 |
| Pantoprazole Sodium | 18 | $147 |
| Prednisone | 17 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $172 | $12,40420 claims |
| MerckDulera | $140 | $7,95914 claims |
| AstraZenecaSymbicort | $372 | $6,14021 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $66 | $5,80619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Bellingham
- Andrew AyarsBellingham$2K
- Taiil SongLakewood$192K
- Frank VirantSeattle$107K
- Richard GowerSpokane$104K
- Leonard AltmanSeattle$81K
- Daniel PetroniSeattle$68K
- David McGarrySpokane Valley$66K
- Rahool DaveSeattle$42K
- Matthew AltmanSeattle$37K
- Arthur VeghTacoma$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.